gdc
PSSGuide_2021
Thyroid Cancer

Drugs for Thyroid Cancer

Here are the drugs and financial support services available to patients receiving treatment for Thyroid Cancer.

Armour Thyroid (thyroid tablets, USP)

Drug company: Allergan
800-222-6885

Armour Thyroid tablets are pituitary thyroid-stimulating hormone suppressants used for the treatment of patients with thyroid cancer.

Allergan offers 1 financial assistance program for patients using Armour Thyroid:

Allergan Patient Assistance Program

Patients who are unable to afford the cost of Armour Thyroid tablets and meet other eligibility requirements are eligible for free medication. Eligible applicants will be enrolled for 12 months and a 90-day supply of medication will be shipped immediately to the physician. Medicare Part D applicants must have been denied the Low Income Subsidy and will only be enrolled until the end of the calendar year.

Caprelsa (vandetanib) Tablets

Drug company: Sanofi Genzyme
800-367-4999

Caprelsa is a kinase inhibitor used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced or metastatic disease.

Caprelsa Access Support offers 3 financial assistance programs for patients using Caprelsa:

Caprelsa Co-Pay Assistance Program

Patients with private insurance whose out-of-pocket costs associated with Caprelsa are more than $50 may be eligible for assistance of up to the program maximum, annually.

Caprelsa Interim Access Program

This program provides a short-term supply of Caprelsa free of charge to patients with private insurance who are experiencing a delay in receiving coverage for this medication.

Sanofi Genzyme Patient Assistance Program

For eligible patients who are uninsured or underinsured, this program may provide Caprelsa free of charge.

Cometriq (cabozantinib)

Drug company: Exelixis
844-900-3273

Cometriq is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Exelixis offers 2 financial assistance programs for patients using Cometriq:

EASE Co-Pay Program

Eligible patients who have private insurance will pay $0 per month for Cometriq, with a maximum limit of $25,000 annually.

EASE Patient Assistance Program

This program provides Cometriq free of charge to patients who do not have insurance coverage and who meet eligibility requirements.

Gavreto (pralsetinib) Capsules

Drug company: Blueprint Medicines
888-258-7768

Gavreto is an oral RET kinase inhibitor used for the treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy. Gavreto is also used for the treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine (if radioactive iodine is appropriate).

Blueprint Medicines offers 4 financial assistance programs for patients who have been prescribed Gavreto:

Co-Pay Assistance Program

Eligible patients who have private insurance may pay as little as $0 for Gavreto. This program covers copay, co-insurance, or deductible expenses for those who qualify.

Patient Assistance Program

Eligible patients who are uninsured or underinsured, and who meet the eligibility requirements, may be able to receive Gavreto for free.

QuickStart Program

Eligible patients who are waiting for insurance coverage approval may be eligible to receive a 15-day supply of Gavreto right away at no cost.

Coverage Interruption Program

Eligible patients who change insurance or experience a temporary interruption in their coverage may receive a supply of Gavreto at no cost.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor and single agent used for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.

Eisai Assistance Program

This program provides Lenvima at no cost to financially needy patients who meet program eligibility criteria.

Mekinist (trametinib)

Drug company: Novartis
800-245-5356

Mekinist is a kinase inhibitor used, in combination with Tafinlar, for the treatment of patients with unresectable or metastatic anaplastic thyroid cancer and a BRAF V600E mutation.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Mekinist:

Novartis Oncology Universal Co-pay Program

Through this program, patients who have private insurance will be responsible for up to $25 monthly in copay and coinsurance. The program pays the balance up to a maximum of $15,000 yearly.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Mekinist for free until prescription drug coverage becomes available to them.

Nexavar (sorafenib) Tablets

Drug company: Bayer
866-639-2827

Nexavar is a kinase inhibitor used for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment.

Bayer’s Resources for Expert Assistance and Care Helpline (REACH) offers 2 financial assistance programs for patients using Nexavar:

Nexavar $0 Co-Pay Program

With this program, patients with private insurance pay a $0 copay for Nexavar, and the program pays up to $25,000, with no monthly maximum.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Nexavar should contact the REACH services counselor to possibly qualify for free medication.

Retevmo (selpercatinib) Capsules

Drug company: Eli Lilly
866-472-8663

Retevmo is RET kinase inhibitor used for the treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy. Retevmo is also used for the treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine (if radioactive iodine is appropriate).

Lilly Oncology offers 2 financial assistance programs for patients who are prescribed Retevmo:

Retevmo Savings Card

Eligible patients who have private insurance may pay as little as $0 for a 30-day supply of Retevmo, subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a maximum annual benefit of $25,000.

Lilly Cares Foundation Patient Assistance Program

For eligible patients who are uninsured or underinsured, and who have a household income at or below 500% of the Federal Poverty Level, this program provides Retevmo for free.

Synthroid (levothyroxine sodium tablets, USP)

Drug company: AbbVie
800-222-6885

Synthroid is used as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

AbbVie offers 2 financial assistance programs for patients using Synthroid:

Synthroid Delivers Program

Patients who have a prescription for Synthroid, regardless of insurance coverage, can receive 30 tablets for $29.50; 60 tablets for $54; and 90 tablets for $75. Patients enrolling in this program may not utilize insurance benefits, including any federal, state, or government-funded insurance program.

AbbVie Patient Assistance Foundation

Patients without insurance and with limited income may qualify to receive free Synthroid. Patients enrolled in Medicare Part D or another insurance program may be eligible for assistance on an exception basis.

Tafinlar (darafenib)

Drug company: Novartis
800-245-5356

Tafinlar is a kinase inhibitor used, in combination with Mekinist, for the treatment of patients with unresectable or metastatic anaplastic thyroid cancer and a BRAF V600E mutation.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tafinlar:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and co-insurance. The program pays the balance up to a maximum of $15,000 yearly.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Tafinlar for free until prescription drug coverage becomes available to them.

Thyrogen (thyrotropin alfa)

Drug company: Sanofi Genzyme
888-497-6436

Thyrogen is used as an adjunctive diagnostic tool for testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Thyrogen is also used as an adjunctive treatment in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Sanofi Genzyme offer 2 financial assistance programs for patients using Thyrogen:

Thyrogen Co-Pay Assistance Program

Eligible patients qualify for a $0 copay, up to a maximum copay assistance amount of $1,000 annually. This may include any combination of copay, co-insurance, or deductible.

Sanofi Genzyme Patient Assistance Program

For patients without insurance or those whose insurance plan does not cover Thyrogen, this Patient Assistance Program may be able to provide Thyrogen free of charge. To learn more, or to determine if you may qualify for assistance, contact your doctor’s office.

Tirosint (levothyroxine sodium)

Drug company: IBSA Pharma
800-587-3513

Tirosint capsules work as pituitary thyrotropin-stimulating hormone suppression and are used for the treatment of patients with thyrotropin-dependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy.

IBSA Pharma offers 2 financial assistance programs for patients using Tirosint:

Tirosint Co-Pay Savings Card

With this savings card, patients are responsible for the first $25 and will receive up to $105 off their out-of-pocket expenses. Insured and cash-paying patients are eligible for the savings card. Medicare and Medicaid patients are not eligible for the program.

Tirosint Direct Program

Through this program, patients can get Tirosint for as little as $40 a month for a 90-day prescription, regardless of insurance coverage.

Table. Drugs Prescribed for Thyroid Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Armour Thyroid (thyroid tablets, USP)
  • Drug company
  • Allergan
  • Indication
  • Treatment of thyroid cancer
  • Patient support services
  • Allergan Patient Assistance Program
    800-222-6885



    Drug name (generic name)
  • Gavreto (pralsetinib) Capsules
  • Drug company
  • Blueprint Medicines
  • Indication
  • Treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy

    Treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine
  • Patient support services
  • Co-Pay Assistance Program
    888-258-7768

    Patient Assistance Program
    888-258-7768

    QuickStart Program
    888-258-7768

    Coverage Interruption Program
    888-258-7768

    Drug name (generic name)
  • Lenvima (lenvatinib) Capsules
  • Drug company
  • Eisai
  • Indication
  • Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
  • Patient support services
  • Lenvima $0 Co-pay Program
    866-613-4724

    Eisai Assistance Program
    866-613-4724


    Drug name (generic name)
  • Nexavar (sorafenib) Tablets
  • Drug company
  • Bayer
  • Indication
  • Treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer, refractory to radioactive iodine treatment
  • Patient support services
  • Nexavar $0 Co-Pay Program
    866-581-4992

    REACH Patient Assistance Program
    866-228-7723

    Drug name (generic name)
  • Retevmo (selpercatinib) Capsules
  • Drug company
  • Eli Lilly
  • Indication
  • Treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy

    Treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine
  • Patient support services
  • Retevmo Savings Card
    866-472-8663

    Lilly Cares Foundation Patient Assistance Program
    800-545-6962

    Drug name (generic name)
  • Synthroid (levothyroxine sodium tablets, USP)
  • Drug company
  • AbbVie
  • Indication
  • Treatment of thyrotropindependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy
  • Patient support services
  • Synthroid Delivers Program
    844-GET-SYNTHRIOD
    (844-438-796847643)

    AbbVie Patient Assistance Foundation
    800-222-6885


    Drug name (generic name)
  • Thyrogen (thyrotropin alfa)
  • Drug company
  • Sanofi Genzyme
  • Indication
  • Adjunctive diagnostic tool for testing for well-differentiated thyroid cancer with previous thyroidectomy

    Adjunct treatment for radioiodine ablation of thyroid tissue remnants, after thyroidectomy for well-differentiated thyroid cancer
  • Patient support services
  • Thyrogen Co-Pay Assistance Program
    888-497-6436

    Sanofi Genzyme Patient Assistance Program
    888-497-6436

    Drug name (generic name)
  • Tirosint (levothyroxine sodium)
  • Drug company
  • IBSA Pharma
  • Indication
  • Treatment of thyrotropindependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy
  • Patient support services
  • Tirosint Co-Pay Savings Card
    833-666-2501

    Tirosint Direct Program
    833-666-2501

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country